ReviewMolecular neurobiology2007
Cannabinoids and multiple sclerosis.
Review in Molecular neurobiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.
- A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms.CNS drugs · 2018Pooled it
- A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.European journal of clinical pharmacology · 2013Trial
- A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.Journal of neurology · 2013Trial
- Genetically Encoded CBInternational journal of molecular sciences · 2026Article
- Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.Pharmacology, biochemistry, and behavior · 2020Review
- Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination.Medicines (Basel, Switzerland) · 2019Review
- Structure-Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives.Frontiers in pharmacology · 2019Article
- Combined CB2 receptor agonist and photodynamic therapy synergistically inhibit tumor growth in triple negative breast cancer.Photodiagnosis and photodynamic therapy · 2018Article
- The Endocannabinoid System and Oligodendrocytes in Health and Disease.Frontiers in neuroscience · 2018Review
- Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway.The Journal of pharmacology and experimental therapeutics · 2016Article
- Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease.Frontiers in cellular neuroscience · 2016Review
- CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?Molecular pharmacology · 2014Review
- Article
- A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray.European journal of clinical pharmacology · 2013Article
- Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2012Review
- Solid-phase parallel synthesis of drug-like artificial 2H-benzopyran libraries.Molecules (Basel, Switzerland) · 2012Review
- Article
- Cannabinoid receptor CB2 protects against balloon-induced neointima formation.American journal of physiology. Heart and circulatory physiology · 2012Article
- Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis.ISRN neurology · 2012Article
- Medical marijuana: clearing away the smoke.The open neurology journal · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review discusses clinical and preclinical evidence that supports the use of cannabinoid receptor agonists for the management of multiple sclerosis. In addition, it considers preclinical findings that suggest that as well as ameliorating signs and symptoms of multiple sclerosis, cannabinoid CB(1) and/or CB(2) receptor activation may suppress some of the pathological changes that give rise to these signs and symptoms. Evidence that the endocannabinoid system plays a protective role in multiple sclerosis is also discussed as are potential pharmacological strategies for enhancing such protection in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.